IBX

2.50%

4.1¢ imagion biosystems limited

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-15

First 15 Last

Share
Profile

Follow
platypusasx

101 Posts.

28

30/01/23

11:23

Post #: 65944416
Share

Originally posted by Dee55Tee: ↑

Finally a GOOD news Quarterly announcement and which is emphatically positive. The planned webinar will hopefully be a solid marketing effort to sell this news and to get the SP moving strongly. There is no doubt now that this technology really works. What are the steps to commercialise this tech - Give us a development timeline that will be delivered on.

The Company Summary of Activities :-
MagSense® HER2 breast cancer study
In early December the Company reported that it had participated in a global breast cancer meeting,
presenting data for the first cohort of patients in its MagSense® HER2 Breast Cancer Phase I study. The
announcement and data presented indicated that the MagSense® HER2 imaging agent is detectable by
both imaging methods being evaluated in the study (conventional MRI and the Company’s proprietary
magnetic relaxometry, MRX). Moreover, that the molecularly targeted nanoparticles exhibit a unique and
observable molecular imaging ‘signature’ when cancer cells are present.
Additionally, during the quarter the Company formed an expert panel of breast cancer radiologists to
undertake an independent blinded review of the MR images. This review aims to corroborate our findings
and aid the Company in defining interpretability and utility for our molecular imaging technology. The
review is in process and expected to be completed in early February 2023. The Company will provide an
update upon completion of the independent review and plans to host a webinar for investors to more fully
address the implications for the Company. The notice of the webinar will be included with the update.
Based on the positive data to date and the fact that the study objectives of safety and detectability are
being met, the Company is now planning for the next phase of development, including studies most likely
in the US. The Phase I study will remain open for enrolment to accumulate additional data that will
contribute to our evaluation of the diagnostic performance and inform future study design considerations.

Expand

Agreed - these are two very great questions that need to be answered.

-What are the steps to commercialise this tech?
-What is the development timeline?

IBX Price at posting: 2.2¢ Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

YAL

Yancoal Australia reports strong Q3 financials

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

TLX

Telix Pharmaceuticals' quarterly revenue exceeds AU$200M

ASX Market Open: ASX set for red Friday after flat night in Wall Street | 18 Oct

THB

Thunderbird picks up plethora of uranium targets based on EM survey in Canada

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

M4M

Macro and Norden set up transport solutions initiative for West Pilbara

TYP

Tryptamine psilocin treatment found safe in IV infusion during early stage trial

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

SGR

Thousands eye Star on HotCopper, SkyCity in strife – are ASX casino stocks safe anymore?

There are more pages in this discussion • 38 more messages in this thread...

First 15 Last

Add IBX (ASX) to my watchlist

(20min delay)
Last 4.1¢		Change 0.001(2.50%)		Mkt cap ! $1.461M

Open	High	Low	Value	Volume
4.1¢	4.4¢	4.0¢	$5.405K	128.8K

Buyers (Bids)

No.	Vol.	Price($)
1	8464	4.1¢

Sellers (Offers)

Price($)	Vol.	No.
4.4¢	43825	1

View Market Depth

No.	Vol.	Price($)
1	8464	0.041
1	100000	0.040
1	26315	0.038
2	30277	0.036
1	48500	0.035

Price($)	Vol.	No.
0.045	12000	1
0.047	14800	1
0.048	1016	1
0.055	88714	1
0.056	11703	2

Last trade - 15.53pm 18/10/2024 (20 minute delay)

IBX (ASX) Chart

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-15

Yancoal Australia reports strong Q3 financials

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Telix Pharmaceuticals' quarterly revenue exceeds AU$200M

ASX Market Open: ASX set for red Friday after flat night in Wall Street | 18 Oct

Thunderbird picks up plethora of uranium targets based on EM survey in Canada

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

Macro and Norden set up transport solutions initiative for West Pilbara

Tryptamine psilocin treatment found safe in IV infusion during early stage trial

Talga Group wins key permit for flagship graphite mine in Sweden

Thousands eye Star on HotCopper, SkyCity in strife – are ASX casino stocks safe anymore?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-15

Top Stories

Yancoal Australia reports strong Q3 financials

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Telix Pharmaceuticals' quarterly revenue exceeds AU$200M

ASX Market Open: ASX set for red Friday after flat night in Wall Street | 18 Oct

Thunderbird picks up plethora of uranium targets based on EM survey in Canada

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

Macro and Norden set up transport solutions initiative for West Pilbara

Tryptamine psilocin treatment found safe in IV infusion during early stage trial

Talga Group wins key permit for flagship graphite mine in Sweden

Thousands eye Star on HotCopper, SkyCity in strife – are ASX casino stocks safe anymore?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News